Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-09-24

Clinical Trial Update: Safety Study of Hepatitis E Vaccine (HEV239) [Phase 1]

View source ↗

Summary

Phase 1 safety trial of the Hepatitis E vaccine HEV239 has completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • HEV239 (HEV239)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Hepatitis E, Immunisation | Phase 1 | Status: COMPLETED | Results posted: 2021-09-24